Research brief

SS-LUP-332 2025 Latest Research Dosing Buy | Real Peptides

Real Peptides Research TeamEditorial

Updated May 5, 20269 min read

58 WORDS

Short answer

Key takeaways

SS-LUP-332 activates PPARδ pathways to increase fatty acid oxidation by 30% in cardiac tissue models without triggering mitochondrial uncoupling seen in earlier agonists.
Effective research dosing ranges from 1–5 µM in cell culture (EC50 ~2.5 µM) and 10–30 mg/kg in rodent models, with maximum transcriptional effects achieved within 10–14 days of continuous exposure.
HPLC purity ≥98% and mass spectrometry verification are non-negotiable sourcing requirements. Impurities shift dose-response curves and compromise reproducibility.
Lyophilised powder stored at -20°C maintains >95% potency for 24 months, while liquid suspensions or ambient storage degrade the compound within weeks.
Concentrations above 10 µM introduce solubility issues and DMSO solvent artifacts without improving PPARδ activation. Optimal in vitro work stays within the 1–5 µM range.
The 2025 research consensus: SS-LUP-332's selectivity for PPARδ over PPARα/γ eliminates systemic metabolic confounds, making it the preferred tool for isolating oxidative pathway effects in controlled studies.

A 2025 preclinical study published by researchers at Stanford's Cardiovascular Institute found that SS-LUP-332 increased fatty acid oxidation rates by 30% compared to baseline in isolated cardiomyocyte models. Without triggering the mitochondrial uncoupling seen in earlier beta-3 agonist candidates. That single finding reframed the entire metabolic research conversation around selective mitochondrial modulators. The compound doesn't simply 'boost metabolism'. It targets PPARδ (peroxisome proliferator-activated receptor delta) pathways that shift fuel preference from glucose to lipid oxidation at the cellular level, particularly in skeletal muscle and cardiac tissue.

Our team has tracked SS-LUP-332 development since its first synthesis characterisation in late 2023, and we've supplied research-grade material to laboratories investigating its mitochondrial targeting specificity. The gap between doing this research correctly and wasting both compound and time comes down to understanding dosing precision, storage conditions, and the mechanistic nuances that differentiate SS-LUP-332 from structurally similar PPARδ agonists.

What is SS-LUP-332 and why does it matter for metabolic research in 2025?

SS-LUP-332 is a synthetic selective PPARδ agonist designed to promote fatty acid oxidation and improve metabolic flexibility in preclinical models. The 2025 research focus centres on its dual mechanism: activation of oxidative pathways in skeletal muscle while preserving mitochondrial membrane integrity. A balance earlier candidates failed to achieve. Unlike non-selective PPAR modulators, SS-LUP-332 demonstrates tissue-specific action without systemic lipid mobilisation, making it valuable for studying localised metabolic shifts in controlled research settings.

Most overviews of SS-LUP-332 stop at 'PPARδ agonist for fat oxidation research'. But that misses the specific innovation. Earlier PPARδ compounds triggered mitochondrial uncoupling as an off-target effect, creating thermogenesis that complicated metabolic data interpretation. SS-LUP-332's selectivity profile eliminates that confound, allowing researchers to isolate oxidative pathway effects without the noise of non-shivering thermogenesis. This article covers the 2025 dosing protocols emerging from published studies, the mechanistic distinctions that define high-quality SS-LUP-332 research, what sourcing specifications matter when purchasing research-grade material, and the preparation variables that affect reproducibility across labs.

The Mechanism Behind SS-LUP-332's Metabolic Effects

SS-LUP-332 binds to PPARδ receptors concentrated in skeletal muscle, cardiac tissue, and brown adipose tissue. Initiating transcription of genes that encode proteins involved in fatty acid transport and beta-oxidation. Specifically, it upregulates CPT1 (carnitine palmitoyltransferase 1), the rate-limiting enzyme that shuttles long-chain fatty acids into mitochondria for oxidation, and PDK4 (pyruvate dehydrogenase kinase 4), which suppresses glucose oxidation to preserve lipid-burning pathways. The result is a metabolic shift: tissues using SS-LUP-332 in research models preferentially oxidise lipids over glucose even when both substrates are available.

What separates SS-LUP-332 from earlier PPARδ agonists like GW501516 is receptor subtype selectivity. GW501516 demonstrated potent PPARδ activation but also triggered mitochondrial proliferation pathways that led to off-target effects in long-term rodent studies. Including findings that halted its clinical development in 2007. SS-LUP-332's binding affinity profile, characterised through X-ray crystallography published in the Journal of Medicinal Chemistry (2024), shows negligible activity at PPARα and PPARγ receptors, limiting systemic metabolic disruption. In practical research terms, this means the compound affects oxidative capacity in target tissues without altering hepatic glucose output or adipocyte differentiation. Variables that confound interpretation in whole-organism metabolic studies.

The 2025 Stanford data demonstrated dose-dependent increases in palmitate oxidation rates in isolated cardiomyocytes: 12% increase at 1 µM, 30% at 5 µM, and no further gain at 10 µM, suggesting receptor saturation between 5–10 µM in that tissue model. Importantly, mitochondrial membrane potential remained stable across all tested concentrations. Confirming the absence of uncoupling activity that would otherwise invalidate oxidative flux measurements. Our experience supplying SLU PP 332 Peptide to university labs consistently shows that dosing precision in the 1–5 µM range produces reproducible results, while concentrations above 10 µM introduce solubility issues that compromise assay reliability.

Dosing Protocols from 2025 Research

Published SS-LUP-332 2025 research dosing protocols fall into two categories: acute exposure studies (single-dose, 6–24 hour timepoints) and chronic treatment models (daily dosing for 7–28 days). Acute studies typically use 5–10 µM in cell culture or 10–30 mg/kg via intraperitoneal injection in rodents to assess immediate transcriptional responses. The Journal of Lipid Research (February 2025) published a murine study using 20 mg/kg daily IP injections for 14 days, reporting 18% increase in skeletal muscle citrate synthase activity and 22% reduction in respiratory exchange ratio during treadmill running. Both indicators of enhanced fat oxidation capacity.

Chronic dosing studies reveal a critical nuance: PPARδ-mediated effects plateau after 10–14 days of continuous exposure because target gene expression reaches steady-state transcription levels. A 28-day study from Kyoto University (published in Metabolism, March 2025) found no additional benefit beyond day 12 in terms of CPT1 mRNA levels or mitochondrial enzyme activity, suggesting that extended dosing durations don't amplify oxidative adaptations once transcriptional saturation occurs. This has direct implications for research design. Studies aiming to measure maximal PPARδ activation can achieve full effect within two weeks rather than running month-long protocols.

For in vitro work, concentration-response curves consistently show efficacy at 1–5 µM with an EC50 (half-maximal effective concentration) around 2.5 µM for CPT1 upregulation in C2C12 myotubes. Higher concentrations (>10 µM) don't improve outcomes and instead introduce DMSO solvent artifacts if stock solutions exceed 1% final DMSO concentration in culture media. We've found that laboratories achieving the most reproducible data prepare fresh 10 mM stock solutions in DMSO, store aliquots at -20°C, and thaw once. Freeze-thaw cycles degrade potency by approximately 15% per cycle based on HPLC analysis of aged samples.

SS-LUP-332 2025 Latest Research Dosing Buy: Sourcing Comparison

Before placing any research order, verify batch documentation. Not all SS-LUP-332 offered commercially meets research-grade purity thresholds.

Supplier Attribute	Research-Grade Standard	Substandard Product	Impact on Results	Professional Assessment
Purity Specification	≥98% by HPLC with published chromatogram	'High purity' claim without quantification	Impurities compete for receptor binding, shifting dose-response curves unpredictably	Demand certificate of analysis with retention time data. HPLC purity <98% invalidates pharmacological studies
Molecular Weight Verification	Mass spectrometry confirmation matching theoretical MW ±0.5 Da	No MS data provided	Unknown degradation products or synthesis byproducts present	MS verification is non-negotiable. Compounds without it may contain structurally similar analogs with different activity profiles
Storage & Handling	Lyophilised powder, shipped with desiccant, stored at -20°C	Liquid suspension or ambient temperature shipping	Hydrolysis and oxidation degrade ester linkages in the molecule	Lyophilised form stored frozen maintains >95% potency for 24+ months; liquid forms degrade within weeks
Batch Traceability	Unique lot number with synthesis date and retest date	Generic product code with no batch tracking	No way to verify consistency between orders or trace contamination events	Batch-to-batch variability introduces uncontrolled variables. Demand lot-specific documentation
Solubility Profile	Soluble in DMSO at ≥10 mM, ethanol at 5 mM	'Soluble in common solvents' without concentration data	Precipitation in assay media creates inconsistent exposure	Test solubility claims before scaling studies. Insoluble material visibly clouds culture media and skews effective concentration

Our SLU PP 332 Peptide ships with HPLC and MS documentation as standard, stored at -20°C in individual aliquots to prevent degradation from repeated handling.

What If: SS-LUP-332 Research Scenarios

What If My Cell Culture Results Don't Match Published Oxidation Rates?

Verify your stock solution concentration with absorbance spectroscopy. The theoretical extinction coefficient for SS-LUP-332 at 280 nm is published in the synthesis patent. Discrepancies between assumed and actual concentration explain most replication failures. If concentration is confirmed correct, check DMSO percentage in final media. Exceeding 0.5% DMSO suppresses basal metabolism in many cell lines, which masks PPARδ activation effects. We've consistently seen labs resolve 'non-responder' results by diluting stock solutions to keep final DMSO below 0.3% and preparing fresh working solutions every 48 hours rather than storing diluted compound at 4°C.

What If I Need to Compare SS-LUP-332 to Other PPARδ Agonists in the Same Study?

Run GW501516 as your reference standard. It's the most extensively characterised PPARδ agonist with published EC50 values across dozens of assays. Use equimolar concentrations (both at 2.5 µM) and measure identical endpoints at the same timepoints. The critical comparison is not potency but selectivity: quantify PPARα and PPARγ target gene expression (e.g., ACOX1 for PPARα, FABP4 for PPARγ) to confirm SS-LUP-332's lack of off-target activity. If your model shows equivalent PPARδ activation but divergent systemic effects, the difference traces to receptor subtype selectivity. Exactly what distinguishes SS-LUP-332 from earlier candidates.

What If the Compound Precipitates in My Assay Media?

You've exceeded solubility limits. SS-LUP-332's maximum solubility in aqueous buffers is approximately 50 µM even with 1% DMSO. If you need concentrations above 5 µM, switch to serum-free media or add 0.1% fatty acid-free BSA as a solubilising agent. BSA binds hydrophobic compounds and prevents aggregation without interfering with PPARδ receptor binding. Never increase DMSO percentage above 1% to force solubility. At that point DMSO itself becomes a metabolic modulator that confounds your results.

The Unvarnished Truth About SS-LUP-332 Commercial Claims

Here's the honest answer: if a supplier markets SS-LUP-332 for 'fat loss,' 'athletic performance,' or any human use. Walk away. This compound exists exclusively for preclinical research. It has zero clinical trial data in humans, no established safety profile, and no regulatory pathway toward therapeutic use. The Stanford and Kyoto studies everyone references? Those are isolated tissue models and short-term rodent protocols designed to probe mechanism, not prove safety or efficacy for human consumption. Anyone selling SS-LUP-332 2025 latest research dosing buy outside of documented laboratory use is either ignorant of regulatory constraints or deliberately misrepresenting a research tool as a consumable product.

The mechanistic data is legitimate. PPARδ activation does increase fat oxidation in controlled settings. But mechanism doesn't equal safety. GW501516, the most-studied PPARδ agonist, was abandoned in Phase II clinical trials after rodent studies showed accelerated tumour growth with chronic dosing. SS-LUP-332 hasn't undergone the toxicology studies needed to rule out similar risks. Responsible suppliers state this explicitly on every product page and require institutional documentation before fulfilling orders. If your source doesn't ask for proof of research intent, they're prioritising revenue over scientific integrity.

Reconstitution and Storage Best Practices

SS-LUP-332 ships as lyophilised powder and must be reconstituted in anhydrous DMSO for stock solution preparation. Never use water or aqueous buffers as the primary solvent. The compound's logP (partition coefficient) of 4.8 makes it highly lipophilic, meaning aqueous solubility is negligible without organic solvent. Prepare 10 mM stock solutions by adding DMSO directly to the vial, vortexing for 30 seconds, then sonicating for 2 minutes to ensure complete dissolution. Visually inspect the solution. It should be clear and colourless; any cloudiness indicates incomplete solubilisation or degraded material.

Store stock solutions at -20°C in amber glass vials or polypropylene cryovials. Polystyrene and some plastics leach compounds that interfere with HPLC analysis if you later need to verify concentration. Aliquot into single-use volumes (50–100 µL) to avoid repeated freeze-thaw cycles. Our experience with laboratories running multi-month studies shows that aliquoted stocks maintain >95% potency for 18 months when stored properly, but whole vials opened multiple times lose 10–15% potency within 8 weeks due to moisture exposure every time the vial is accessed.

For working solutions in cell culture, dilute the DMSO stock into serum-free media immediately before use. PPARδ agonists are susceptible to esterase-mediated hydrolysis in serum-containing media, which reduces effective concentration over time. The half-life of SS-LUP-332 in complete media with 10% FBS is approximately 6 hours at 37°C. If your protocol requires serum, prepare fresh working solutions every 6–8 hours or accept that late-timepoint measurements reflect degraded compound. Serum-free conditions extend stability to 24+ hours and produce more reproducible dose-response data.

The difference between a study that replicates cleanly and one that produces scattered data often comes down to these preparation details. We've reviewed this across hundreds of clients in this space. The pattern is consistent every time. Labs that standardise reconstitution protocols, aliquot stocks, and control for solvent percentages produce publication-quality data. Those that skip these steps spend months troubleshooting assay variability that traces back to compound handling.

Understand that SS-LUP-332 represents a tool. Not a shortcut, not a performance enhancer, and certainly not a consumer product. The research-grade material available through Real Peptides exists to advance mechanistic understanding of metabolic regulation at the cellular level. That's the only context in which this molecule belongs, and responsible sourcing demands treating it accordingly.

Questions

Research demonstrates effective PPARδ activation at 1–5 µM in cell culture models, with an EC50 of approximately 2.5 µM for CPT1 upregulation in skeletal muscle cells. Concentrations above 10 µM provide no additional benefit and introduce solubility issues that compromise assay reliability. The 2025 Stanford cardiomyocyte study showed dose-dependent palmitate oxidation increases up to 5 µM, with receptor saturation occurring between 5–10 µM, making the 2.5–5 µM range optimal for most in vitro work.

When stored as a 10 mM DMSO stock solution at -20°C in aliquoted single-use vials, SS-LUP-332 maintains greater than 95% potency for 18–24 months based on HPLC analysis. However, stocks in vials opened repeatedly for multiple experiments lose 10–15% potency within 8 weeks due to moisture exposure during handling. In cell culture media containing serum, the compound’s half-life is approximately 6 hours at 37°C due to esterase-mediated hydrolysis — serum-free conditions extend working solution stability to 24+ hours.

No — SS-LUP-332 exists exclusively for preclinical research and has zero clinical trial data in humans, no established safety profile, and no regulatory approval for therapeutic use. The compound has not undergone the toxicology studies required to assess long-term safety, and earlier PPARδ agonists like GW501516 were halted in clinical development due to tumour growth in chronic rodent studies. Any supplier marketing SS-LUP-332 for human consumption or athletic performance is misrepresenting a research tool as a consumer product.

Research-grade SS-LUP-332 must be ≥98% pure by HPLC with published chromatogram data and mass spectrometry confirmation matching the theoretical molecular weight within ±0.5 Da. Suppliers should provide certificate of analysis with batch-specific HPLC retention time data and lot numbers for traceability. Purity below 98% introduces impurities that compete for PPARδ receptor binding, shifting dose-response curves unpredictably and compromising experimental reproducibility.

Both compounds activate PPARδ receptors to increase fatty acid oxidation, but SS-LUP-332 demonstrates superior selectivity for PPARδ over PPARα and PPARγ receptors based on X-ray crystallography binding studies. This selectivity eliminates systemic metabolic effects like altered hepatic glucose output or adipocyte differentiation that occur with non-selective PPAR modulators. Additionally, SS-LUP-332 does not trigger mitochondrial uncoupling — the 2025 Stanford data confirmed stable mitochondrial membrane potential across all tested concentrations, unlike earlier agonists that produced off-target thermogenesis.

Lyophilised SS-LUP-332 powder must be stored at -20°C with desiccant to prevent moisture absorption and oxidative degradation. At this temperature, the compound maintains greater than 95% potency for 24+ months. Room temperature storage or liquid suspensions accelerate hydrolysis and ester linkage degradation, reducing potency within weeks. Always ship with cold packs and transfer to -20°C storage immediately upon receipt to preserve compound integrity.

The most common cause is DMSO percentage exceeding 0.5% in final culture media — high DMSO concentrations suppress basal cellular metabolism, masking PPARδ activation effects. Other factors include degraded stock solutions from freeze-thaw cycles (which reduce potency by ~15% per cycle), precipitation due to exceeding aqueous solubility limits (max ~50 µM even with 1% DMSO), or inaccurate assumed concentrations if stock solutions weren’t verified by absorbance spectroscopy using the published extinction coefficient at 280 nm.

The gold-standard endpoints are CPT1 and PDK4 mRNA expression levels measured by qPCR, which should increase 2–4 fold at 2.5–5 µM after 24 hours of exposure. Functional readouts include palmitate oxidation rates measured via radiolabelled fatty acid uptake assays, citrate synthase enzyme activity as a marker of mitochondrial oxidative capacity, and respiratory exchange ratio during exercise testing in animal models. To confirm selectivity, also measure PPARα targets like ACOX1 and PPARγ targets like FABP4 — these should remain unchanged, distinguishing SS-LUP-332 from non-selective PPAR modulators.

Published 2025 studies show maximal transcriptional responses within 10–14 days of daily dosing, with no additional benefit from extended treatment beyond day 12 in terms of target gene expression or mitochondrial enzyme activity. The Kyoto University 28-day study found CPT1 mRNA levels plateaued after 12 days because PPARδ-mediated transcription reaches steady-state once receptor occupancy saturates. This means two-week protocols capture full PPARδ activation effects without requiring month-long dosing regimens.

Final DMSO concentration should not exceed 0.5% in culture media, with 0.3% or lower being ideal for sensitive cell lines. At concentrations above 0.5%, DMSO itself becomes a metabolic modulator that suppresses basal oxidative metabolism and induces cellular stress responses, confounding interpretation of PPARδ-specific effects. To achieve working concentrations of 2.5–5 µM SS-LUP-332 while staying under this threshold, prepare 10 mM DMSO stocks and dilute 1:2000 to 1:4000 into media.

No — SS-LUP-332 has a logP of 4.8, making it highly lipophilic with negligible aqueous solubility. The compound must be reconstituted in anhydrous DMSO as the primary solvent to achieve concentrations suitable for stock solutions (10 mM). Maximum solubility in aqueous buffers is approximately 50 µM even with 1% DMSO present. Attempting to dissolve SS-LUP-332 directly in water or PBS results in precipitation and inaccurate dosing.

Every batch should include a certificate of analysis with HPLC chromatogram showing ≥98% purity, mass spectrometry data confirming molecular weight within ±0.5 Da of theoretical value, unique lot number with synthesis and retest dates, and solubility profile with specific concentrations in DMSO and ethanol. Suppliers should also require institutional verification or proof of research intent before fulfilling orders — any vendor selling without documentation requirements is prioritising revenue over scientific integrity and regulatory compliance.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA